Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma

por Schreck, Karisa C, Allen, Amy N, Wang, Jiawan, Pratilas, Christine A
Publicado 2020

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

por Odeniyide, Patience, Yohe, Marielle E., Pollard, Kai, Vaseva, Angelina V., Calizo, Ana, Zhang, Lindy, Rodriguez, Fausto J., Gross, John M., Allen, Amy N., Wan, Xiaolin, Somwar, Romel, Schreck, Karisa C., Kessler, Linda, Wang, Jiawan, Pratilas, Christine A.
Publicado 2022

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

por Odeniyide, Patience, Yohe, Marielle E., Pollard, Kai, Vaseva, Angelina V., Calizo, Ana, Zhang, Lindy, Rodriguez, Fausto J., Gross, John M., Allen, Amy N., Wan, Xiaolin, Somwar, Romel, Schreck, Karisa C., Kessler, Linda, Wang, Jiawan, Pratilas, Christine A.
Publicado 2022

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma

por Schreck, Karisa C., Morin, Andrew, Zhao, Guisheng, Allen, Amy N., Flannery, Patrick, Glantz, Michael, Green, Adam L., Jones, Chris, Jones, Kenneth L., Kilburn, Lindsay B., Nazemi, Kellie J., Samuel, David, Sanford, Bridget, Solomon, David A., Wang, Jiawan, Pratilas, Christine A., Nicolaides, Theodore, Mulcahy Levy, Jean M.
Publicado 2021